Plain-English translation of NCT05211557 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new treatment called fhB7H3.CAR-T cells for women with ovarian cancer that has returned or stopped responding to standard chemotherapy. Researchers will collect your immune cells, grow them in a laboratory to recognize and attack cancer cells, and then put them back into your body. The goal is to see if this personalized immune therapy is safe and effective.
Current treatments for recurring ovarian cancer often don't work well enough, and many patients develop fluid buildup in their abdomen (ascites) that is hard to treat. This trial is testing whether a new approach using engineered immune cells might help patients whose cancer has come back.
You likely qualify if…
You likely don't qualify if…
First, doctors will confirm your cancer has the right marker and collect immune cells from your blood, which will be grown in a lab for several weeks. When ready, you'll receive chemotherapy for three days to prepare your body, then the new immune cells will be infused directly into your abdomen. You'll have frequent blood and fluid checks in the first month, then monthly visits for three months, then every three months for a year, and finally yearly visits for five years total.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China